61
Participants
Start Date
September 7, 2018
Primary Completion Date
October 29, 2021
Study Completion Date
October 29, 2021
LUM
Fixed Dose Combination (FDC) granules (LUM/IVA).
IVA
FDC granules (LUM/IVA).
University of Rochester Medical Center, Rochester
Children's Hospital of Philadelphia, Philadelphia
Nemours / Alfred I. duPont Hospital for Children, Wilmington
Johns Hopkins Hospital, Baltimore
Wake Forest University School of Medicine - Brenner Children's Hospital, Winston-Salem
University of North Carolina Hospitals, Chapel Hill
Children's Healthcare of Atlanta, Atlanta
University of Alabama at Birmingham, Birmingham
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children at Indiana University Health, Indianapolis
University of Wisconsin Hospital and Clinics, Madison
Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota, Minneapolis
Ann & Robert Lurie Children's Hospital of Chicago, Chicago
Cardinal Glennon Children's Hospital - St. Louis University, St Louis
The Children's Mercy Hospital, Kansas City
Arkansas Children's Hospital, Little Rock
Children's Medical Center of Dallas, Dallas
Cook Children's Medical Center, Fort Worth
Children's Hospital Colorado, Aurora
University of Utah / Primary Children's Medical Center, Salt Lake City
Stanford University, Palo Alto
Seattle Children's Hospital, Seattle
Yale New Haven Medical Center, New Haven
Boston Children's Hospital, Boston
McGill University Health Centre, Glen Site, Montreal Children's Hospital, Montreal
The Hospital for Sick Children, Toronto
British Columbia's Children's Hospital, Vancouver
Vertex Pharmaceuticals Incorporated
INDUSTRY